文献速递免疫规划

免疫调节肽GK-1静脉与皮下给药在小鼠乳腺癌模型中的抗肿瘤效果与安全性比较

Antitumoral effectiveness and safety of intravenous versus subcutaneous administration of immunomodulatory peptide GK-1 in a murine breast cancer model.
PubMed 文献 · Vaccine · 2025-02-01

本研究在4T1小鼠乳腺癌模型中比较GK-1皮下与静脉给药的抗肿瘤效果及心肾安全性。两种途径均显著延长小鼠寿命、缩小原发肿瘤并减少肺大转移,且均降低肿瘤浸润淋巴细胞PD-1表达,未见心肾损伤,支持皮下给药疗效不劣于静脉且安全性相似。

要点

  • 皮下或静脉给予GK-1均显著延长4T1荷瘤小鼠寿命并减小原发肿瘤。
  • 两种途径均显著减少肺大转移并降低肿瘤浸润淋巴细胞PD-1表达。
  • 无瘤小鼠中未检测到心肾组织损伤,皮下给药疗效不劣于静脉。

核心结论

  • 本研究支持皮下给予GK-1的疗效不劣于静脉给药,耐受良好且安全性特征相似,因此提供了一种创伤更小的有效治疗选择。

研究设计与样本

  • BALB/c雌性小鼠原位注射1000个4T1细胞,触及约1 mm3原发肿瘤后每周给予GK-1(5 mg/kg)静脉或皮下注射,持续21天。
  • 每周监测肿瘤生长和小鼠体重,开始治疗28天后记录原发肿瘤重量和体积、肺转移数目及PD-1表达。
  • 另取无瘤小鼠的肾、心、脾、血清和血样,用特异性细胞毒性标志物评估GK-1给药对这些组织的损伤程度。

主要发现

  • 皮下或静脉给予GK-1均显著延长小鼠寿命,并显著降低原发肿瘤重量和体积及肺大转移数目。
  • 无论采用何种免疫途径,GK-1均降低小鼠肿瘤浸润淋巴细胞的PD-1表达。
  • 无瘤小鼠中未检测到肾或心组织损伤的证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: GK-1 is a safe and effective molecule with high antimetastatic activity against murine breast and skin cancer. GK-1 treatment enhances cytotoxic response of CD8+ lymphocytes against the tumor and modifies the oxidative stress in the tumor. This study was designed to compare the antitumor efficacy of GK-1 by subcutaneous (SC) versus intravenous (IV) route of administration in the 4T1 mouse mammary carcinoma model and to extend its innocuity in heart and kidney, key tissues for observing damage induced by anticancer drugs and immunotherapy. MATERIAL AND METHODS: BALB/c female mice were injected orthotopically with 1000 4T1 cells. When palpable primary tumors of about 1 mm3 were detected, GK-1 (5 mg/kg) was administered IV or SC weekly for 21 days. Tumor growth and mouse weight were monitored weekly. The primary tumor weight and volume, the number of lung metastases, and programmed cell death protein 1 (PD-1) expression were recorded after 28 days of starting treatment. Kidney, heart, spleen, serum, and blood samples from naïve mice were obtained to evaluate the safety of GK-1 administration by measuring the degree of damage to these tissues with specific cytotoxic markers. RESULTS: Subcutaneous or intravenous administration of GK-1 significantly increased the lifespan of mice and significantly reduced the primary tumor weight and volume and the number of lungs macrometastases. GK-1 reduced the expression of PD-1 in tumor-infiltrating lymphocytes in mice regardless of the route of immunization used, which is especially encouraging. No evidence of damage to kidney or heart tissues was detected in the tumor-free mice. CONCLUSIONS: This study supports that subcutaneous GK-1 administered, has an efficacy non-inferior to intravenous administration, well-tolerated with a similar safety profile and therefore offers a less invasive valid treatment alternative.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hernández-Aceves JA, Cervantes-Torres J, Cruz-Gregorio A, et al. Antitumoral effectiveness and safety of intravenous versus subcutaneous administration of immunomodulatory peptide GK-1 in a murine breast cancer model. Vaccine. 2025. PMID: 39893770. doi:10.1016/j.vaccine.2025.126814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。